VENCLEXTA offers patients with CLL/SLL the only oral-based, chemo-free regimens with fixed treatment duration of 12 months* for 1L CLL and ~24 months for R/R CLL 1

*The VEN+G regimen is designed to be completed after 12 months (twelve 28-day treatment cycles): GAZYVA® (obinutuzumab) is administered in Cycles 1-6, and VENCLEXTA is taken orally 400 mg/day from Cycle 3, Day 1, after the first cycle of GAZYVA and the 5-week VENCLEXTA dose ramp-up.
The VEN+R regimen is designed to be completed after ~24 months (twenty-four 28-day treatment cycles after the 5-week VENCLEXTA dose ramp-up): rituximab is administered at 375 mg/m2 on Day 1, Cycle 1 and 500 mg/m2 on Day 1, Cycles 2-6; VENCLEXTA is taken 400 mg/day orally from Cycle 1, Day 1 of rituximab through Cycle 24.

Drug cost refers to the Wholesale Acquisition Cost. Coverage and patient out-of-pocket costs for VENCLEXTA-based regimens vary by health plan. Patients may still incur out-of-pocket costs for other treatments or tests as directed by their healthcare providers.

CLL=chronic lymphocytic leukemia; SLL=small lymphocytic lymphoma; 1L=first line; R/R=relapsed/refractory; VEN+G=VENCLEXTA + GAZYVA; VEN+R=VENCLEXTA + rituximab.